Pfizer, Inc. (PFE) Receives Buy Rating from BMO Capital Markets

BMO Capital Markets reaffirmed their buy rating on shares of Pfizer, Inc. (NYSE:PFE) in a research report released on Wednesday. The firm currently has a $37.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on the company. Citigroup Inc. downgraded Pfizer from a neutral rating to a sell rating and cut their target price for the stock from $38.00 to $31.00 in a research report on Tuesday, May 16th. Credit Suisse Group downgraded Pfizer from an outperform rating to a neutral rating and cut their target price for the stock from $38.00 to $36.00 in a research report on Thursday, July 20th. Zacks Investment Research upgraded Pfizer from a sell rating to a hold rating in a research report on Friday, July 14th. Morgan Stanley restated a neutral rating and set a $35.00 target price (down previously from $38.00) on shares of Pfizer in a research report on Monday, June 12th. Finally, ValuEngine downgraded Pfizer from a buy rating to a hold rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $37.61.

Pfizer (NYSE:PFE) opened at 34.10 on Wednesday. Pfizer has a 52 week low of $29.83 and a 52 week high of $34.75. The company’s 50-day moving average price is $33.36 and its 200-day moving average price is $33.49. The company has a market capitalization of $202.80 billion, a P/E ratio of 24.95 and a beta of 1.00.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. Pfizer’s revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the company earned $0.64 EPS. On average, equities analysts forecast that Pfizer will post $2.56 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Pfizer, Inc. (PFE) Receives Buy Rating from BMO Capital Markets” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2017/09/10/pfizer-inc-pfe-receives-buy-rating-from-bmo-capital-markets.html.

The company also recently announced a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were paid a $0.32 dividend. The ex-dividend date was Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.75%. Pfizer’s dividend payout ratio (DPR) is currently 94.12%.

In related news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction on Friday, September 1st. The stock was sold at an average price of $34.00, for a total value of $249,900.00. Following the sale, the insider now directly owns 124,774 shares of the company’s stock, valued at $4,242,316. The disclosure for this sale can be found here. Insiders sold a total of 426,291 shares of company stock valued at $14,475,911 over the last three months. Insiders own 0.06% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Asset Planning Services Ltd. grew its stake in shares of Pfizer by 4.9% during the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares during the period. Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer during the second quarter worth $102,000. Mckinley Capital Management LLC Delaware acquired a new stake in shares of Pfizer during the second quarter worth $103,000. D. Scott Neal Inc. grew its stake in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares during the period. Finally, Orrstown Financial Services Inc. grew its stake in shares of Pfizer by 23.0% during the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 612 shares during the period. 69.09% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply